 HASBROUCK HEIGHTS, N.J., March 29, 2021 GLOBE NEWSWIRE -- Nymox Pharmaceutical Corporation NASDAQ: NYMX is pleased to provide the latest update on the Companys regulatory filing preparation activities. The Company expects to file for approval for its first in class BPH treatment Fexapotide Triflutate, during the summer of this year. Management will provide a firm exact date for the filing in a subsequent disclosure. This communication of the exact date for the filing will be announced by the Company within the next 6 weeks. If there are any unexpected events that delay that announcement, the Company will provide immediate relevant updates. 